PTC Therapeutics (NASDAQ:PTCT) EVP Lee Scott Golden Sells 866 Shares

PTC Therapeutics, Inc. (NASDAQ:PTCT) EVP Lee Scott Golden sold 866 shares of the firm’s stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $76.45, for a total transaction of $66,205.70. Following the transaction, the executive vice president directly owned 92,428 shares in the company, valued at $7,066,120.60. This trade represents a 0.93% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Lee Scott Golden also recently made the following trade(s):

• On Wednesday, January 7th, Lee Scott Golden sold 642 shares of PTC Therapeutics stock. The stock was sold at an average price of $77.48, for a total transaction of $49,742.16.
• On Tuesday, January 6th, Lee Scott Golden sold 1,340 shares of PTC Therapeutics stock. The shares were sold at an average price of $76.95, for a total transaction of $103,113.00.

PTC Therapeutics Stock Performance

NASDAQ:PTCT traded up $0.06 during trading hours on Monday, reaching $77.59. The company’s stock had a trading volume of 2,631,928 shares, compared to its average volume of 1,795,906. The stock has a 50 day moving average price of $76.61 and a two-hundred day moving average price of $62.91. The company has a market capitalization of $6.23 billion, a P/E ratio of 9.06 and a beta of 0.49. PTC Therapeutics, Inc. has a 12 month low of $35.95 and a 12 month high of $87.50.

PTC Therapeutics (NASDAQ:PTCT) last announced its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.19) by $1.39. The business had revenue of $211.01 million for the quarter, compared to the consensus estimate of $177.42 million. PTC Therapeutics had a negative return on equity of 194.11% and a net margin of 42.25%.The business’s revenue was up 7.2% compared to the same quarter last year. During the same period last year, the business posted ($1.39) EPS. As a group, analysts predict that PTC Therapeutics, Inc. will post -4.52 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently commented on PTCT. The Goldman Sachs Group increased their target price on shares of PTC Therapeutics from $44.00 to $50.00 and gave the company a “sell” rating in a research report on Wednesday, November 5th. Wells Fargo & Company upped their price target on PTC Therapeutics from $73.00 to $93.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 5th. Morgan Stanley reissued an “overweight” rating and issued a $90.00 price objective on shares of PTC Therapeutics in a research report on Thursday. Royal Bank Of Canada downgraded PTC Therapeutics from an “outperform” rating to a “sector perform” rating and boosted their target price for the stock from $82.00 to $91.00 in a research note on Monday, December 1st. Finally, TD Cowen upped their target price on PTC Therapeutics from $50.00 to $63.00 and gave the company a “hold” rating in a research report on Wednesday, November 5th. Nine equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $77.27.

Institutional Trading of PTC Therapeutics

Several large investors have recently added to or reduced their stakes in PTCT. Smartleaf Asset Management LLC boosted its holdings in PTC Therapeutics by 101.3% during the third quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 236 shares in the last quarter. Optiver Holding B.V. grew its position in shares of PTC Therapeutics by 96.5% during the 3rd quarter. Optiver Holding B.V. now owns 507 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 249 shares during the period. Comerica Bank grew its position in shares of PTC Therapeutics by 868.5% during the 3rd quarter. Comerica Bank now owns 523 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 469 shares during the period. IFP Advisors Inc increased its stake in shares of PTC Therapeutics by 68.1% in the 3rd quarter. IFP Advisors Inc now owns 765 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 310 shares in the last quarter. Finally, PNC Financial Services Group Inc. increased its stake in shares of PTC Therapeutics by 42.1% in the 2nd quarter. PNC Financial Services Group Inc. now owns 995 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 295 shares in the last quarter.

PTC Therapeutics News Roundup

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Company update: PTC reported unaudited Q4 Sephience global revenue of $92.5M, unaudited 2025 product and royalty revenue of ~ $823M (above guidance), and provided 2026 product revenue guidance of $700–800M (implying ~19–36% YoY growth). Management also reported a strong cash balance of ~ $1.94B as of Dec. 31 — the combination supports near-term growth and a healthy balance sheet. PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference
• Neutral Sentiment: Conference transcript: Management’s JPM presentation (transcript) reiterated commercial execution, pipeline priorities, and the company’s strategy for scaling Sephience — helpful for modeling sales cadence and upcoming milestones but containing no major surprises beyond the PR release. PTC Therapeutics Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
• Negative Sentiment: Insider selling: Multiple senior executives (including the CEO and CFO) sold shares in early January in transactions totaling hundreds of thousands of dollars, which can create short‑term selling pressure or investor concern about insider conviction even if sales may be for diversification or liquidity reasons. Insider Selling: CEO Sells Insider Selling: CFO Sells
• Negative Sentiment: Additional executive stock sales reported across several filings (EVP, VP and others) increase the volume and visibility of insider dispositions in the same window — monitor SEC Form 4s for context on intent and frequency. PTC Therapeutics CEO Sells $396,215.55 in Stock

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.